MDXG MiMedx Group Inc.

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company’s EPIFIX® Placental Allograft Product

MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology: “Placental allograft reconstruction of cutaneous wounds following Mohs surgery: a propensity score-matched comparative cost-effectiveness analysis.”

Mohs surgery is widely accepted as the gold standard for treating many types of skin cancer, including basal and squamous cell carcinomas, which are the most common cancers in the United States. MMS is performed over 850,000 times per year in the U.S., primarily by specially trained dermatologists operating in an outpatient setting. The procedure, which involves the removal of layers of cancerous skin tissue, typically ends with an autologous tissue-based closure over the treatment area. However, over the last several years, practitioners have increasingly started to evaluate the utility of placental allografts, such as EPIFIX, to aid in the closure of the impacted surface.

“We are thrilled to continue expanding the number of specialties and treatment applications that see real-world results with our products, both in terms of clinical success and cost-effectiveness,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “This retrospective study of 429 Mohs patients demonstrates the unique ability of our placental allografts to provide an alternative for those who are not suitable candidates for traditional surgical methods. We expect the data collected to inform clinicians and health policy makers of the benefits of innovative approaches in high-risk surgeries, particularly as hospital systems focus on health economics as a driving factor in decision-making.”

In the study, DHACM significantly reduced adverse post-repair sequelae, with 97.2% of patients experiencing no complications compared to 78.7% with traditional methods such as autologous tissue-based flaps and grafts. Placental allografts lead to substantial savings in these procedures by minimizing postoperative complications and reducing the need for additional procedures. Patients treated with placental tissue also reached closure faster, with an average length of care of 33.3 days compared to 48.3 days for those with autologous tissue repairs.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
05/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

MIMEDX to Present at the BofA Securities 2025 Healthcare Conference MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. Presentation Details: Tuesday, May 13, 20255:15 p.m. PDT Investors interested in meeting with senior management at this event may contact their Bank of America representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade ...

 PRESS RELEASE

MIMEDX Announces Publication of Health Economics Data in Mohs Microgra...

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS) Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company’s EPIFIX® Placental Allograft Product MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology...

 PRESS RELEASE

MIMEDX Announces First Quarter 2025 Operating and Financial Results

MIMEDX Announces First Quarter 2025 Operating and Financial Results Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operati...

 PRESS RELEASE

MIMEDX to Host First Quarter 2025 Operating and Financial Results Conf...

MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30 MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: ...

 PRESS RELEASE

MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at ...

MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. “MIMEDX’s ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be on ful...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch